Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/21/2025

Switching Clonidine IR to Long-Acting Formulation

Conversion Algorithm

  • The American College of Cardiology recommends that a patient on clonidine 0.2mg twice daily IR can be directly switched to the transdermal patch formulation at an equivalent dose, specifically the 0.1mg/24hr patch applied weekly 1, 2
  • The transdermal clonidine patch delivers drug at a constant rate over 7 days, with available patch strengths including 0.1mg/24hr, 0.2mg/24hr, and 0.3mg/24hr 1, 2
  • For a 0.4mg/day oral dose, the American College of Cardiology suggests starting with the 0.1mg/24hr patch, equivalent to approximately 0.7mg/week or 0.1mg/day 1, 2

Critical Safety Considerations

  • The American Heart Association, as published in Circulation, warns that never abruptly discontinuing clonidine without tapering or transitioning to the patch can precipitate severe rebound hypertension and hypertensive crisis 1, 2

Advantages of Transdermal Formulation

  • The American College of Cardiology notes that the transdermal formulation improves medication adherence with once-weekly application 1, 2

Common Pitfalls to Avoid

  • The American College of Cardiology recommends rotating patch application sites to prevent skin irritation 1, 2
  • If a patch falls off before 7 days, the American College of Cardiology suggests applying a new patch immediately and adjusting the weekly schedule 1, 2